{"filings":[{"id":1342398,"accession_number":"0001645113-26-000056","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-06-30T11:00:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure's Optune Pax receives CE Mark for locally advanced pancreatic cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CE Mark supported by Phase 3 PANOVA-3 trial showing statistically significant mOS improvement.","mOS 16.2 vs 14.2 months (HR 0.82, p=0.039) in ITT; 18.3 vs 15.1 months in mITT.","Time to pain progression extended 6.1 months (15.2 vs 9.1 months, HR 0.74, p=0.027).","Optune Pax already FDA-approved Feb 2026; launch in Germany planned in coming weeks.","Device well-tolerated; most AEs mild-moderate skin events; no new safety signals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1120321,"accession_number":"0001645113-26-000053","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-06-18T11:00:03+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure Phase 3 TRIDENT trial fails to show survival benefit for early TTFields in GBM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS 17.7 mo (Early Start) vs 17.5 mo (Maintenance Start); HR 0.953, p=0.519.","981 patients enrolled; 25% did not initiate maintenance phase across both arms.","1-/2-/3-year survival rates: Early Start 70.9%/33.9%/22.5%; Maintenance 72.0%/31.6%/18.4%.","No new safety signals; TTFields with chemoradiation was well-tolerated.","Results accepted for presentation at ASTRO 2026 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":889159,"accession_number":"0001645113-26-000050","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-06-05T20:29:35+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NovoCure shareholders elect 11 directors, approve incentive plan by slim margin at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with 79.5M to 82.5M for votes; term expires 2027.","Ratified Kost Forer Gabbay & Kasierer as independent auditor for FY2026: 91.4M for, 2.3M against.","Advisory vote to approve executive compensation passed: 75.4M for vs 7.4M against.","Amended & Restated 2024 Omnibus Incentive Plan approved by narrow margin: 41.68M for, 41.16M against (plus 10.87M broker non-votes).","93.8M shares represented (81% of entitled) at the June 3, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94348,"accession_number":"0001645113-26-000043","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure Q1 net revenue $174M (+12% YoY); raises FY2026 guidance; Optune Pax launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $71.1M ($0.62 per share); Adjusted EBITDA of -$0.3M.","Gross margin improved to 78% (from 75%) on lower array costs.","Optune Pax FDA approved for locally advanced pancreatic cancer; 169 prescriptions, 83 active patients as of March 31, 2026.","FY2026 revenue guidance raised to $690M-$710M (from $675M-$705M); Adj. EBITDA guidance narrowed to -$15M-$0M.","PANOVA-4 Phase 2 met primary endpoint with 74% disease control rate vs 48% historical control."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":174055000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94346,"accession_number":"0001645113-26-000038","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K/A","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NovoCure discloses CEO Frank Leonard's pay: CHF 750K base, 90% target bonus, enhanced severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of CHF 750,000 and target annual bonus of 90% of base (CHF 675,000).","Eligible for equity awards under 2024 Omnibus Incentive Plan; relocation and tax indemnification provided.","Severance on qualifying termination: 100% base salary; within 12 months post-change-in-control: 200% base + 200% target bonus plus full equity vesting.","Non-compete covenant for 12 months after termination; perpetual non-disparagement.","Amendment filed to supplement Dec. 1, 2025 8-K; compensation details now finalized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94347,"accession_number":"0001645113-26-000026","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NovoCure names Dr. Uri Weinberg CMO, adds CHF 5k/month stipend","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Uri Weinberg, previously Chief Innovation Officer, also appointed Chief Medical Officer effective April 7, 2026.","Monthly salary increased by CHF 5,000 (gross) for the duration of the CMO assignment.","Stipend not included in annual incentive payment (AIP); all other terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106631,"accession_number":"0001645113-26-000023","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure PANOVA-4 trial meets primary endpoint; DCR 74.4% vs 48% historical control in mPDAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PANOVA-4 met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431), 1-sided p<0.001.","Secondary endpoints: ORR 34.6% (95% CI 24.2%-46.2%), median OS 9.7 months (95% CI 7.9-12.7 months).","TTFields therapy with atezolizumab and gem/nab-pac well-tolerated; safety consistent with prior studies.","Novocure plans to present further PANOVA-4 data at a future scientific forum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106630,"accession_number":"0001645113-26-000018","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure reports Q4 2025 revenues up 8% to $174M; FDA approves Optune Pax for pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved Optune Pax for locally advanced pancreatic cancer in Feb 2026; expands addressable market significantly.","Q4 2025 net revenue $174.4M (+8% YoY); full year $655.4M (+8%). Q4 net loss $24.5M ($0.22 loss per share).","2026 guidance: revenue $675-705M; Adjusted EBITDA ($20M)-$0M; Optune Lua/Pax revenue $15-25M.","Frank Leonard appointed CEO Dec 2025; CMO Nicolas Leupin resigned Feb 2026; CMS billing privileges reinstated.","Active patients on TTFields therapy globally totaled 4,620 at Dec 31, 2025; GBM prescriptions up 6%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106629,"accession_number":"0001645113-26-000013","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CMS rescinds retroactive revocation of Novocure's Medicare billing privileges","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS revoked billing privileges retroactive to Dec 17, 2025; cited administrative re-validation issue, not substantive failure.","On Feb 24, 2026, CMS rescinded revocation and reinstated privileges retroactively to Dec 17, 2025.","Company continued patient services during revocation and expects no impact on revenue recognition.","Revocation letter dated Jan 29, 2026; resolution achieved within one month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106628,"accession_number":"0001645113-26-000010","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approval based on Phase 3 PANOVA-3 trial in 571 patients with locally advanced pancreatic cancer.","Median overall survival improved to 16.2 months vs 14.2 months (HR 0.82, p=0.039).","Time to pain progression extended by 6.1 months (15.2 vs 9.1 months).","First new treatment approved for locally advanced pancreatic cancer in nearly 30 years.","Optune Pax well-tolerated; most adverse events were mild-to-moderate skin reactions under arrays."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106627,"accession_number":"0001645113-26-000007","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NovoCure receives CMS billing revocation; expects ~$13M/month revenue impact until reinstatement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS revoked NovoCure's billing privileges retroactive to Dec 17, 2025 due to an administrative re-validation process issue.","Company estimates approximately $13 million per month in lost revenue from CMS payors until privileges are reinstated.","NovoCure has filed a Corrective Action Plan and expects reinstatement, but cannot predict timing with certainty.","Company continues to provide services to existing and new patients; will attempt to bill for services during reinstatement.","Financial impact and ultimate outcome cannot be determined at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106626,"accession_number":"0001645113-26-000003","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NovoCure reports record FY2025 revenue $655M (+8% YoY); appoints Frank Leonard as CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2025 net revenue $655.4M (+8% YoY); Q4 revenue $174.4M (+8% YoY).","Cash and investments $448.3M after repaying $561M convertible notes due Nov 2025.","Active TTFields patients reached 4,620 globally; Optune Gio prescriptions +6% in Q4.","Frank Leonard, previously President, appointed CEO in December 2025.","Filed PMA for TTFields in brain metastases from NSCLC; topline data expected Q1-Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":655353000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122958,"accession_number":"0001645113-25-000045","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Novocure appoints President Frank Leonard as CEO; Ashley Cordova resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ashley Cordova resigned as CEO and director effective Nov 30, 2025; no disagreement related to operations.","Frank Leonard, previously President, becomes CEO effective Dec 1, 2025; he joined Novocure in 2010.","Cordova enters garden leave through May 31, 2026, with salary, benefits, bonus, and CHF 375,000 cash payment.","Leonard led global business operations since Jan 2024 and prior innovation/product development.","Executive Chairman William Doyle cites Leonard as ideal for upcoming transformative milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122957,"accession_number":"0001645113-25-000043","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NovoCure Q3 revenue $167M (+8% YoY), net loss $37.3M; PMA for pancreatic cancer under review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues of $167.2M, up 8% YoY; US contributed $96.6M, Germany $20.3M, France $19.6M, Japan $9.4M.","Net loss of $37.3M ($0.33 loss per share); adjusted EBITDA of $(3.0)M; gross margin 73% vs 77% YoY.","4,416 active patients globally as of Sept 30, 2025; Optune Gio prescriptions up 7% to 1,675.","PMA for TTFields in locally advanced pancreatic cancer accepted by FDA; PMA for brain metastases from NSCLC planned Q4 2025.","Cash and short-term investments $1,033.5M; Spain coverage for Optune Gio; Japan approval for Optune Lua with PD-1/L1."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":481003000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139664,"accession_number":"0001645113-25-000037","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Japan MHLW approves Novocure's Optune Lua for advanced NSCLC","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Japan MHLW approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors in advanced/recurrent NSCLC after platinum-based chemo.","Approval based on Phase 3 LUNAR trial: median OS 13.2 vs 9.9 months (3.3-month improvement, p=0.04).","In PD-1/PD-L1 subgroup, median OS 19.0 vs 10.8 months (8.2-month improvement, p=0.02).","Optune Lua is a wearable TTFields device; device-related AEs were mostly grade 1-2 skin reactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139663,"accession_number":"0001645113-25-000032","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NovoCure terminates LUNAR-4 phase 2 trial for metastatic NSCLC, cites real-world evidence alternative","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novocure GmbH terminated the LUNAR-4 phase 2 trial of Tumor Treating Fields with pembrolizumab for metastatic non-small cell lung cancer.","Decision based on availability of real-world evidence to achieve trial objectives without an interventional clinical study.","Termination is not related to any safety concerns; no impact on other Novocure studies.","Trial targeted patients previously treated with PD-1/PD-L1 inhibitor and platinum-based chemotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139662,"accession_number":"0001645113-25-000030","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NovoCure Q2 2025 revenue $158.8M (+6% YoY), net loss $40.1M; plans pancreatic cancer PMA in Q3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $158.8M, up 6% YoY; net loss $40.1M ($0.36 loss per share); adjusted EBITDA -$9.9M.","4,331 active patients on TTFields globally; Optune Gio active patients up 7% YoY.","Phase 3 PANOVA-3 pancreatic cancer trial met primary endpoint; PMA submission to FDA planned Q3 2025.","PMA for brain metastases from NSCLC planned H2 2025; TRIDENT and PANOVA-4 readouts expected H1 2026.","Cash and investments $911.5M as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":313799000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157242,"accession_number":"0001645113-25-000011","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NovoCure shareholders elect 11 directors, approve ESPP; President awarded 179,426 RSUs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected all 11 director nominees with >81M votes each; 92.98M shares represented (~83.4%).","Say-on-pay approved: 80.6M for, 2.0M against, ~10M broker non-votes.","2025 Employee Share Purchase Plan approved: 82.0M for, 0.68M against; reserves 6,507,843 shares (less prior plan shares).","Francis Leonard appointed President, Novocure and awarded 179,426 RSUs vesting in two equal annual installments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157241,"accession_number":"0001645113-25-000010","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Phase 3 PANOVA-3 trial meets primary endpoint; median OS improved to 16.2 vs 14.2 months (HR 0.82, p=0.039)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival 16.2 months with TTFields + GnP vs 14.2 months for GnP alone; HR 0.82, p=0.039.","One-year survival rate 68.1% vs 60.2% (p=0.029).","Median pain-free survival 15.2 months vs 9.1 months; 6.1-month extension (HR 0.74, p=0.027).","TTFields therapy well-tolerated with mild to moderate skin adverse events; no new safety signals.","Company plans to file for FDA PMA approval in second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157240,"accession_number":"0001645113-25-000009","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure Q1 revenue $155M (+12% YoY), net loss $34.3M; CE Mark for Optune Lua NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $155M, +12% YoY; net loss $34.3M ($0.31 loss per share); adj. EBITDA -$5.0M; cash $929M.","Active patients 4,268; Optune Gio active patients +9% to 4,162; Optune Lua patients 106 (62 NSCLC, 44 MPM).","CE Mark approved for Optune Lua with immune checkpoint inhibitors or docetaxel in metastatic NSCLC after platinum progression.","Tariff risk: up to $11M if tariffs resume post-90-day pause; up to $8M if pause extended; monitoring mitigation.","PANOVA-3 Phase 3 pancreatic cancer results accepted as late-breaking abstract at ASCO 2025; milestones H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":154994000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157239,"accession_number":"0001645113-25-000007","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure's Optune Lua receives CE Mark for metastatic NSCLC treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CE Mark for Optune Lua in mNSCLC with immune checkpoint inhibitors or docetaxel after platinum progression.","Phase 3 LUNAR trial: median OS 13.2 months (Optune Lua) vs 9.9 months (control); primary endpoint met.","Subgroup with immune checkpoint inhibitor: median OS 18.5 vs 10.8 months (P=0.03).","Local registration initiated in Germany; launch expected in coming weeks. FDA approval received Oct 2024.","Post-market study of TTFields with docetaxel required as condition; 180 patients, 12-month follow-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175612,"accession_number":"0001645113-25-000003","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure FY2024 revenue $605M (+19%), Q4 net loss $65.9M; Optune Lua approved and launched; PANOVA-3 trial met endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net revenues $605.2M (+19% YoY); Q4 net revenues $161.3M (+21% YoY).","Q4 net loss $65.9M ($0.61/sh); adjusted EBITDA $2.6M; cash $959.9M.","Optune Lua received FDA approval Oct 2024 for metastatic NSCLC; 52 prescriptions by year-end.","Phase 3 PANOVA-3 trial met primary endpoint in unresectable locally advanced pancreatic cancer.","2025 outlook: low mid-single digit GBM growth; margins impacted by product launches."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":605220000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175611,"accession_number":"0001645113-25-000001","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NovoCure reports preliminary FY2024 net revenues $605M (+19% YoY); Q4 $161M (+21%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2024 net revenues $605.2M (+19% YoY); Q4 $161.3M (+21% YoY).","Active patients globally: 4,126 total on TTFields; 4,077 Optune Gio; 52 Optune Lua prescriptions for NSCLC.","Cash, cash equivalents and short-term investments $959.9M as of Dec 31, 2024.","FDA approved Optune Lua for metastatic NSCLC in Oct 2024; Phase 3 PANOVA-3 trial met primary endpoint in pancreatic cancer.","FY2025 revenue growth expected to align with Optune Gio active patient growth; US prior-period claims added $8.3M in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":605220000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192559,"accession_number":"0001645113-24-000036","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K/A","filed_at":"2024-12-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Novocure details CEO Cordova compensation; Danziger transition terms set","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ashley Cordova named CEO effective Jan 1, 2025; base salary CHF 750K, target bonus 90% of base.","Cordova severance: 100% base (non-CIC) or 200% base + 200% target bonus (CIC); equity fully vests on CIC termination.","Asaf Danziger transitions to Senior Advisor through Dec 31, 2026; base salary $700K in 2025, then $120K.","Danziger receives 400,000 RSUs vesting Dec 31, 2025 and 2026; forfeits certain PSUs upon CEO resignation.","Both subject to 12-month non-compete, perpetual confidentiality, and non-disparagement covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192562,"accession_number":"0001645113-24-000034","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure's PANOVA-3 Phase 3 trial meets primary endpoint in pancreatic cancer; plans regulatory filings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PANOVA-3 met primary endpoint: mOS 16.20 months (TTFields) vs 14.16 months (control), HR=0.819, p=0.039 (N=571).","Survival rate benefit increased over time: 13% improvement at 12 months, 33% improvement at 24 months.","TTFields therapy was well-tolerated; safety consistent with prior studies.","Novocure plans regulatory filings in U.S., EU, Japan, and other key markets based on PANOVA-3.","This is Novocure's third positive Phase 3 trial in two years; full results at upcoming congress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192561,"accession_number":"0001645113-24-000033","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"NovoCure Q3 revenue +22% to $155M; FDA OKs Optune Lua; CEO/CFO transitions set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenues $155.1M (+22% YoY); net loss $30.6M ($0.28 loss per share); adjusted EBITDA $1.7M.","FDA approved Optune Lua for metastatic NSCLC; Breakthrough Device designation for brain metastases from NSCLC.","CEO Asaf Danziger retiring Jan 1, 2025; CFO Ashley Cordova to become CEO on that date.","Christoph Brackmann appointed CFO (from Moderna), effective Jan 1, 2025; compensation disclosed.","Active patients on therapy 4,113; prescriptions up 8% to 1,586; cash and equivalents $959.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":443954000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192560,"accession_number":"0001645113-24-000030","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA approves Novocure's Optune Lua for metastatic NSCLC after platinum progression","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Optune Lua approved for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in patients with mNSCLC who progressed on/after platinum-based therapy.","Phase 3 LUNAR trial: median OS 13.2 months (Optune Lua + therapy) vs 9.9 months (control); 3.3-month gain (P=0.04).","In PD-1/PD-L1 subgroup, median OS 19.0 months vs 10.8 months; 8.2-month gain (P=0.02).","Device-related AEs in 63.1% of patients; mostly low-grade skin toxicity; no Grade 4/5 or deaths.","First substantial OS improvement in >8 years for this patient population; wearable TTFields device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209027,"accession_number":"0001645113-24-000029","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"NovoCure CEO Asaf Danziger to retire Jan 1, 2025; CFO Ashley Cordova appointed CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Asaf Danziger, in role since 2002, retires Jan 1, 2025; will remain on board and advise until early 2026.","CFO Ashley Cordova named CEO effective Jan 1, 2025; she will stay as CFO until successor appointed.","COO Wilco Groenhuysen resigns effective Oct 1, 2024; Mukund Paravasthu promoted to COO.","Groenhuysen entered new employment agreement: base salary $615K/yr to Sept 2025 then $120K/yr to Apr 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209026,"accession_number":"0001645113-24-000018","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NovoCure Q2 revenue $150M (+19% YoY), net loss $33.4M, METIS trial positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $150.4M, up 19% YoY; U.S. contributed $95.7M, Germany $15.1M, France $14.3M.","Net loss $33.4M ($0.31 per share); adjusted EBITDA $1.1M; cash and investments $951.2M.","Phase 3 METIS trial in brain metastases from NSCLC met primary endpoint; presented at ASCO 2024.","Active patients 3,963 as of June 30, 2024; prescriptions 1,634, up 5% YoY.","Gross margin 77%; research & development expenses $55.0M; sales & marketing $56.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":288859000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226876,"accession_number":"0001645113-24-000016","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders elect 10 directors, approve 2024 Omnibus Incentive Plan at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 85.9M shares (79.8% of eligible) voted at June 5 AGM; all 10 director nominees elected.","Auditor ratification passed: 80.1M for, 5.7M against, 0.09M abstain.","Non-binding advisory vote on executive compensation approved: 69.6M for, 1.2M against.","2024 Omnibus Incentive Plan approved: 60.1M for (73.7% of votes cast), 10.8M against.","Say-on-pay frequency set at one year: 70.5M for one year vs 0.4M for three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226875,"accession_number":"0001645113-24-000015","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NovoCure's METIS phase 3 trial data in brain metastases to be presented at ASCO 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract for METIS phase 3 trial in brain metastases from NSCLC available May 23 on ASCO website.","Oral presentation scheduled for June 3 at 10:24 AM CDT during CNS Tumors session.","No data disclosed yet; trial results are pending presentation at ASCO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226874,"accession_number":"0001645113-24-000014","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NovoCure Q1 net revenue up 13% to $138.5M; METIS trial meets endpoint, FDA decision on lung cancer PMA expected H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $138.5M (+13% YoY); net loss $38.8M ($0.36 loss per share); adjusted EBITDA -$4.6M.","Active patients 3,845; prescriptions received 1,643 (+10% YoY).","METIS Phase 3 met primary endpoint (brain metastases from NSCLC); will be presented at ASCO.","LUNAR PMA for Optune Lua in NSCLC: Day 100 FDA meeting productive, decision expected H2 2024.","Entered $400M senior secured credit facility with Pharmakon Advisors (non-dilutive)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":138503000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245823,"accession_number":"0001645113-24-000009","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure METIS Phase 3 trial meets primary endpoint; intracranial progression delay 21.9 vs 11.3 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TTFields + supportive care showed median time to intracranial progression of 21.9 months vs 11.3 months for supportive care alone (HR=0.67, p=0.016).","Key secondary endpoints (neurocognitive failure, overall survival, radiological response) did not reach statistical significance.","Median TTFields therapy duration was 16 weeks, median usage 67%; therapy well-tolerated with sustained quality of life.","Novocure plans to submit data to regulatory authorities and publish findings in a peer-reviewed journal.","Phase 3 METIS trial enrolled 298 patients with 1-10 brain metastases from NSCLC following stereotactic radiosurgery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245822,"accession_number":"0001645113-24-000007","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure reports Q4 net loss $47.1M, full year revenue down 5%; NSCLC PMA accepted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 net revenues $509.3M, down 5% YoY; Q4 net revenues $133.8M, up 4% YoY.","Q4 net loss $47.1M ($0.45 loss per share); adjusted EBITDA -$31.6M.","Active patients 3,755 (+9% YoY); prescriptions 1,564 (+14% YoY).","FDA accepted PMA for TTFields in NSCLC; enrollment completed in phase 3 TRIDENT trial.","Cash, cash equivalents and short-term investments $910.6M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":509338000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245821,"accession_number":"0001645113-24-000005","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA accepts Novocure's PMA for TTFields in NSCLC post-platinum; decision H2 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PMA application accepted for filing; FDA begins substantive review.","Submission filed Dec 15, 2023; regulatory decision expected in second half 2024.","TTFields therapy plus standard systemic therapies for NSCLC after progression on platinum-based therapy.","CEO states milestone brings therapy closer to patients with few non-toxic options.","Application based on LUNAR trial data in post-platinum NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245820,"accession_number":"0001645113-24-000004","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure completes enrollment in Phase 3 TRIDENT trial for newly diagnosed glioblastoma; data expected 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final patient enrolled in global Phase 3 TRIDENT trial (950 patients) evaluating Optune Gio concurrent with radiation + temozolomide for newly diagnosed GBM.","Patients randomized to TTFields + TMZ + radiation vs TMZ + radiation for 6 weeks, then all receive standard care (TTFields + maintenance TMZ).","Primary endpoint is overall survival; secondary endpoints include PFS, safety, quality of life, and radiological response.","Top-line data from the trial is anticipated in 2026; enrollment began in December 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245819,"accession_number":"0001645113-24-000003","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure reports preliminary 2023 revenue $509M (-5% YoY); NSCLC PMA submitted to FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY 2023 net revenues $509.3M, down 5% YoY on reduced US claim collections.","Q4 2023 net revenues $133.8M, up 4% YoY; US contributed $91.3M, Germany $14.7M.","1,564 prescriptions in Q4 (+14% YoY); 3,755 active patients (+9% vs Q4 2022).","PMA application for TTFields in NSCLC submitted to FDA/PMDA in December 2023.","Appointed Dr. Nicolas Leupin as Chief Medical Officer effective Jan 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":509338000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245818,"accession_number":"0001645113-24-000002","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Novocure appoints Dr. Nicolas Leupin as CMO; Pritesh Shah steps down as executive officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Nicolas Leupin appointed CMO, overseeing medical affairs, safety, and clinical development.","Pritesh Shah resigns as executive officer; to serve as Senior Advisor to CEO through June 30, 2025.","Frank Leonard appointed EVP and President, Novocure Oncology; base salary $525,000, target bonus 60%.","Shah's salary drops from $500k to $120k after June 2024; equity grants continue vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263290,"accession_number":"0001645113-23-000050","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure announces $60M cost-cutting plan, cuts 200 jobs (13% of workforce)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction in residual operating expenses of ~$60M; includes 200 job cuts (13% of staff).","One-time restructuring charge of ~$7M expected in Q4 2023.","Pivots resources to launch readiness for metastatic NSCLC Tumor Treating Fields therapy.","Plans two Phase 3 readouts in 2024: METIS (brain mets NSCLC) and PANOVA-3 (pancreatic).","Prioritizes clinical trials TRIDENT, KEYNOTE D58, LUNAR-2 for greatest value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263289,"accession_number":"0001645113-23-000048","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure Q3 net revenues $127.3M (-3% YoY); net loss $49.5M as INNOVATE-3 misses endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $127.3M, down 3% YoY; US contributed $86.2M, Germany $14.7M, Japan $7.6M.","Net loss $49.5M ($0.46 loss per share); adjusted EBITDA $(29.1)M.","3,639 active patients on therapy as of Sept 30, 2023; prescriptions up 6% YoY to 1,467.","Phase 3 INNOVATE-3 (ovarian cancer) did not meet primary overall survival endpoint at final analysis.","Cash & short-term investments $921.2M; gross margin 75%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":375554000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280483,"accession_number":"0001645113-23-000046","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NovoCure's INNOVATE-3 trial fails primary endpoint: no OS benefit in ovarian cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS 12.2 months (TTFields + paclitaxel) vs 11.9 months (paclitaxel alone); HR 1.008.","540 patients enrolled; trial designed for platinum-resistant ovarian cancer.","TTFields therapy well-tolerated without added systemic toxicities.","Exploratory subgroup suggests potential survival benefit in patients with only one prior therapy line.","Full data analysis ongoing; results to be shared with scientific community."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280482,"accession_number":"0001645113-23-000045","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure Q2 net revenue $126M (-11% YoY); phase 3 LUNAR NSCLC trial meets primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $57.4M ($0.54 per share); adjusted EBITDA -$27.2M; active patients 3,571.","LUNAR trial: median OS 13.2 months TTFields+standard vs 9.9 months standard alone (HR=0.74, p=0.035).","Revenue decline largely due to $13.4M reduced collections from previously denied U.S. claims.","Prescriptions up 13% to 1,556; U.S., Germany, Japan contributed 981, 204, and 92 respectively.","PANOVA-3 (pancreatic) DMC recommends proceeding to final analysis; LUNAR-2 trial IDE accepted by FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":248233000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280481,"accession_number":"0001645113-23-000043","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NovoCure PANOVA-3 pancreatic cancer trial passes interim DMC review; continues to final analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent DMC recommended continuation of phase 3 PANOVA-3 trial for unresectable, locally advanced pancreatic cancer.","Trial evaluating TTFields plus nab-paclitaxel/gemcitabine is fully enrolled; final data expected in 2024.","No efficacy or safety data disclosed; trial proceeds as planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299069,"accession_number":"0001645113-23-000042","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NovoCure annual meeting: directors re-elected, compensation advisory passes with 33% dissent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; William Doyle and Timothy Scannell received highest against votes (~2.3M and ~3.4M).","Ratification of Ernst & Young as auditor for FY2023 approved with 87.4M for, 1.2M against.","Non-binding advisory vote on executive compensation passed with 52.2M for, 25.3M against (~33% against).","Approximately 83.5% of shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299068,"accession_number":"0001645113-23-000041","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Phase 3 LUNAR trial meets primary endpoint: TTFields + SOC improves OS in NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median OS 13.2 months for TTFields+SOC vs 9.9 months for SOC alone (HR 0.74, p=0.035).","In ICI subgroup, median OS 18.5 vs 10.8 months (HR 0.63, p=0.03); in docetaxel 11.1 vs 8.7 months (HR 0.81, p=0.28).","No added systemic toxicities; most common device effect was grade 1-2 dermatitis (43%).","Company plans to submit for regulatory approval; first-line NSCLC studies underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299067,"accession_number":"0001645113-23-000040","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NovoCure presents positive phase 3 LUNAR trial results for TTFields in NSCLC at ASCO","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Positive results from phase 3 LUNAR trial of TTFields plus standard therapies for NSCLC announced at ASCO 2023.","Data presented on June 6, 2023; filing does not disclose specific efficacy or safety metrics.","Company intends to discuss regulatory submission for potential NSCLC indication expansion.","Ticker NVCR; positive clinical milestone for TTFields therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299066,"accession_number":"0001645113-23-000039","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Novocure LUNAR phase 3 trial meets primary endpoint; median OS improved 3 months in NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LUNAR trial met primary endpoint: median OS 13.2 mo (TTFields+SOC) vs 9.9 mo (SOC alone); HR 0.74, p=0.035.","ICI subgroup showed median OS 18.5 mo (TTFields+ICI) vs 10.8 mo (ICI alone); HR 0.63, p=0.03.","TTFields therapy well-tolerated with no added systemic toxicities; few grade 3 device-related AEs.","One-year survival 53% vs 42% (p=0.04); three-year survival 18% vs 7% (p=0.015).","Novocure plans PMA submission to FDA in H2 2023 based on LUNAR data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299065,"accession_number":"0001645113-23-000038","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Novocure Q1 2023: Revenue down 11% to $122M, net loss $53.1M, prescriptions up 8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenues $122.2M (-11% YoY); US $85.2M, Germany $15.1M, Japan $8.7M.","Net loss $53.1M ($0.50 loss per share); adjusted EBITDA -$18.4M.","Prescriptions received 1,496 (+8% YoY); active patients 3,467 as of March 31.","R&D expenses +41% to $59.7M on clinical trial activity; sales & marketing +35%.","Phase 3 LUNAR NSCLC data to be presented at ASCO June 6; METIS enrollment completed, data Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":122182000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299064,"accession_number":"0001645113-23-000036","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Novocure LUNAR phase 3 NSCLC trial met primary endpoint; results at ASCO 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LUNAR trial showed statistically significant improvement in overall survival with TTFields plus standard therapies in metastatic NSCLC.","Full results to be presented as a late-breaking abstract at ASCO 2023 on June 6, 2023, at 11:09 a.m. CDT.","Novocure will host an investor event on June 6 at 2 p.m. CDT to discuss the data.","First phase 3 trial evaluating TTFields outside the brain and with immunotherapy.","Ten abstracts on TTFields therapy, including LUNAR, will be presented at ASCO 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319235,"accession_number":"0001645113-23-000032","cik":1645113,"company_name":"NovoCure Ltd","ticker":"NVCR","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Novocure elects Kristin Stafford to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kristin Stafford elected to Novocure board effective March 28, 2023.","She is SVP, Chief Accounting Officer at Royalty Pharma plc.","She receives option grant of $667,000 fair value, vesting over three years.","She joins Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1983433538.4343734,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-29T23:59:59+00:00|319235"}